anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will look at the impact of care delivery by a specialist respiratory doctor compared to general practitioners for patients with COPD in East Birmingham. It will be run from the Heart of England NHS Foundation Trust, which will provide the specialist input and oversight, and up to 40 practices across the Eastern Birmingham Health Organisation with approximately 2200 patients with COPD confirmed by their current medical practitioner. Each practice will be randomised to either the intervention or control group. The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations. Treatment will be at the discretion of the clinician and is not specified in the trial protocol. The investigators anticipate that the treatment recommendations in the intervention arm may include referral to pulmonary rehabilitation and reduction in the use of inhaled corticosteroids, which are prescribed at high rates in our locality. The control group will be seen by the usual staff at their practice. These patients will not be seen by the trial team and their data will be extracted remotely using electronic systems.

The primary outcome will be to compare the rates of provision of guideline-based care in intervention and control practices. Secondary outcomes will include: referral to secondary care, unscheduled healthcare consultations (ED attendance, hospital admissions), COPD exacerbations, healthcare costs, medications prescribed, biochemical markers of disease, radiological investigations, lung function tests measured when clinically indicated, and death within 12 month follow-up period.
In the HS environment, the resident will be exposed to various stressors. There will be the presence of audio alarms as well as the presence of a senior physician who will be supervising the performance of the resident. In addition, the mannequin will be slightly unstable which will be reflected in its oxygen saturation dropping throughout the first 30 seconds the procedure.
The sustainable lifestyle group will receive instructions to increase the consumption of healthy organic plant-based foods that is carbon or environmentally friendly (i.e. fruits, vegetables, legumes, multigrain cereals, or labeled foods) and decrease consumption of beef and dairy products. We expect that the reduction of diet-related CO2e will be 50% as compared to the baseline, while the intake of nutrients such as fiber, vitamin C, and folate will increase. Additionally, they will receive instructions to increase active and emission-free transportation, i.e. walking and biking to and from work and meetings.
PURPOSE: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease involving synovial inflammation and joint destruction. Although therapeutic drugs for RA have some efficacy, they usually cause severe side effects and are expensive. RA is characterized by synovial hyperplasia, intra-articular hypoxia, upregulated expression of matrix metalloproteinases, and excessive accumulation of reactive oxygen species. The adverse microenvironment further aggravates activated macrophage infiltration. Therefore, controlling the microenvironment of diseased tissues and targeting the activated macrophages have become new therapeutic targets in RA patients.
METHODS: Here, microenvironment-targeting micelles (PVGLIG-MTX-Que-Ms) were synthesized using the thin film hydration method. In the inflammatory microenvironment, PVGLIG was cleaved by the highly expressed MMP-2, PEG5000 was eliminated, MTX was exposed, macrophage activation was targeted, and Que enrichment was enhanced. The cytotoxicity, targeting, antioxidant, and anti-inflammatory properties of drug-loaded micelles were tested in vitro. The drug-loaded micelles were used to treat CIA rats. In vivo targeting, expression of serum inflammatory factors, immunohistochemistry of the articular cartilage, and changes in immunofluorescence staining were observed.
RESULTS: The developed micelles had a particle size of (89.62 ±1.33) nm and a zeta potential of (-4.9 ±0.53) mV. The IC50 value of PVGLIG-MTX-Que-Ms (185.90 ±6.98) μmol/L was significantly lower than that of free Que (141.10 ±6.39) μmol/L. The synthesized micelles exhibited slow-release properties, low cytotoxicity, strong targeting abilities, and significant anti-inflammatory effects in vitro. In vivo, the drug-loaded micelles accumulated at the joint site for a long time. PVGLIG-MTX-Que-Ms significantly reduced joint swelling, improved bone destruction, and decreased the expression of serum inflammatory factors in CIA rats.
CONCLUSION: The smart-targeting micelles PVGLIG-MTX-Que-Ms with strong targeting, anti-inflammatory, cartilage-protective, and other multiple positive effects are a promising new tool for RA treatment.
PURPOSE:A carcinostatic adjuvant, consisting of an extracted essence of SANOSHASHINTO (containing Rhei Rhizoma, Scutellariae Radix and Coptidis Rhizoma) and useful as a drug capable of reducing side effect of cisplatin normally used as a carcinostatic agent. CONSTITUTION:A carcinostatic adjuvant containing an extracted essence of SANOSHASHINTO containing Rhei Rhizoma, Scutellariae Radix and Coptidis Rhizoma. Although cisplatin is a carcinostatic agent effective for orchioncus, prostatic cancer, vesical cancer, ovarian cancer and renal pulvis and urethral tumor, renopathy, splenopathy, gastroenteropathy, etc., are recognized and the renopathy is particularly remarkable. This is a regulation factor for dose of the cisplatin. The constituent weight ratio of the SANOSHASHINTO is Rhei Rhizoma (1-2), Scutellariae Radix (1-1.5) and Coptidis Rhizoma (1-1.5). The extracted essence has hitherto been used for treating accompanying symptoms of hypertension, etc., but has action on reduction of side effect of the cisplatin. The SANOSHASHINTO is capable of suppressing the rise in BUN value caused by the cisplatin and further reducing the lethal toxicity of the cisplatin without affecting the carcinostatic effect thereof.
BACKGROUND: Our objective was to elucidate the pivotal roles of BCAR1 in unfolded protein response (UPR), autophagy and vasculogenic mimicry (VM) formation, processes that essential for the metastasis of lung adenocarcinoma (LUAD) cells.
METHODS: The morphological assessment of endoplasmic reticulum (ER) status and autolysosomes in H1975 and H1299 LUAD cells following BCAR1 knockout (KO) was conducted using transmission electron microscope. The expression of markers and cellular functions related to the UPR, autophagy, and VM formation were examined in LUAD cells tissues. Additionally, proteomic analysis of LUAD cells was performed via mass spectrometry, and the pertinent signaling pathways were analyzed using bioinformatics tools.
RESULTS: BCAR1-KO inhibited autophagy and UPR induced triggered starvation in LUAD cells. Cleaved-ATF6a-mediated UPR and subsequent autophagy, enhanced by BCAR1, were confirmed using the UPR stimulator and blocker. High BCAR1 expression, along with elevated UPR and autophagy, predicts poor prognosis in LUAD patients. BCAR1-KO reduced tube formation and VM markers expressions in LUAD cells. Additionally, BCAR1 expression positively correlated with VM formation in BALB/c-nu mice xenografts and LUAD patient tissues.
CONCLUSION: BCAR1 promotes LUAD metastasis by enhancing cancer cell survival in nutrient-poor environments through ATF6-mediated UPR activation and autophagy. As BCAR1 induces VM formation, metastatic lesions eventually colonize. Thus, BCAR1 is a promising anti-metastasis target.
Patients receive prednisone PO, prednisolone IV, or methylprednisolone IV on days 1-5. Patients also receive rituximab IV, polatuzumab vedotin IV over 30-90 minutes, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After a baseline week of self-monitoring their meat consumption participants will be asked to try and reduce their meat consumption over the next eight weeks, with no further guidance. They will be invited back to complete log their meat consumption of the previous day during weeks five and nine (follow-up 1 and 2).
BACKGROUND Polycystic ovary syndrome (PCOS) is among the most common endocrine disorders in premenopausal women, affecting 7-10% of this population. This syndrome is characterized by hyperandrogenism, chronic anovulation and, frequently, obesity. Hyperandrogenemia seems to be a consistent reproductive phenotype in male relatives as well as female relatives of PCOS women. This phenotype appears to have a genetic basis in PCOS families and shows significant linkage and association with a marker locus on chromosome 19p in the region of the insulin receptor (allele 8 of D19S884.). This allele is also recently found to be associated with a metabolic phenotype in PCOS probands and their brothers, including increased post-challenge glucose levels, apparent defects in insulin secretion, especially in response to sulfonylurea, and accelerated weight gain with age (unpublished date). Therefore, allele 8 status in PCOS probands and their family members can identify the reproductive and metabolic abnormalities.

Many epidemiologic studies showed a plausible link between low birth weight and chronic metabolic disorders manifested as hypertension, diabetes and obesity later in life, suggestive of an early fetal programming. There is evidence to support fetal origin of PCOS. Female rhesus monkeys that were exposed to excess androgen in utero, were born smaller for gestational age. These animals had many of the reproductive features of PCOS, including increased LH levels, irregular ovulation, polycystic ovaries and functional ovarian hyperandrogenism. Similarly, in retrospective cohort studies, girls with elevated adrenal androgen levels or with PCOS were significantly smaller for gestational age at birth than reproductively normal control girls, suggestive of a possible fetal origin for some features of PCOS in human studies. Molecular mechanism for fetal programming is not clearly understood, but permanent changes in gene expression caused early insult may be a factor.

HYPOTHESIS These observations have led to a new hypothesis for the etiology of PCOS; genetic variation resulting in hyperandrogenemia leads to many of the reproductive and metabolic features of PCOS later in life. We will directly test the hypothesis that there is an excess androgen production in female offspring of women with PCOS. Further, we will test whether A8(+) female offspring have more profound changes in these parameters (increased androgen and/or decreased insulin levels in fetal life and in infancy) compared to A8(-) female offspring.
Apparatus for concealing vitiligo and unwanted tan lines is provided. The apparatus includes a cosmetic applicator. The cosmetic applicator includes a spring head. The spring head may be covered by a covering. Depression of the spring head may saturate the covering with a solution. The solution may include a bronzer and dihydroxyacetone ("DHA").
In this group patients will performed pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention was performed 60 min per day, 3 times per week, for a total of 24 sessions, within a 8 week period. The longer session duration was designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program was performed prior to cycling.
Preparation of active therapeutic proteins comprising two essential steps. In the first step an active protein source is treated under conditions sufficient to inactivate any viruses present (e.g. via heat or chemical treatment).      In the second step, the treated active protein source of moderate purity is then treated under conditions sufficient to remove impurities as well as denatured (once active) proteins resulting from the viral inactivation step. In an illustrative embodiment, a biologically active protein such as antithrombin is treated under conditions sufficient to assure viral inactivation and minimal antithrombin deactivation. After the viral inactivation, the antithrombin is contacted with immobilized heparin to complex only the active antithrombin which is then eluted by known means and processed further (e.g., to include desired excipients and then freeze dried). The preferred resulting concentrate is characterized by a high degree of purity, virus inactivation, and absence of denatured or inactive protein (generally less than about 10% by weight inactive form or, in the case of antithrombin, less than about 10% as determined, for example, by crossed immunoelectrophoresis).
FIELD: chemico-pharmaceutical industry, particularly, creation of polyvitamin preparation with mineral additives. SUBSTANCE: preparation includes nucleus containing retinol acetate, α-tocopherol acetate, thiamine chloride, riboflavin-mononucleotide, pyridoxine hydrochloride, ascorbic acid, folic acid, nicotineamide, rutin, calcium pantothenate, cyanocobalamin, lipoic acid, iron (II) sulfate, copper sulfate, calcium phosphate, cobalt (II) sulfate, manganese sulfate, zinc sulfate, magnesium phosphate, citric acid, sugar, calcium stearate, talc, potato starch, envelope containing main magnesium carbonate, wheat flour, sugar, beeswax, titanium dioxide, methylcellulose, talc, and gelatin. The proposed method of producing tabletted polyvitamin preparation with mineral additives involves addition of mixture from cyanocobalamin with sugar powder and mixture of folic acid with starch to granulate I prepared from calcium phosphate, ascorbic acid, thiamine chloride, pyridoxine hydrochloride, and rutin. Then granulate II from calcium pantothenate, lipoic acid, nicotineamide, riboflavin-mononucleotide, α-tocopherol acetate, calcium phosphate and granulate III prepared from iron (II) sulfate heptahydrate, magnesium phosphate disubstituted, cobalt (II) sulfate heptahydrate, manganese (II) sulfate pentahydrate, copper sulfate, zinc sulfate hentahydrate, citric acid and polyvinylpyrrolidone are mixed, retinol acetate in granules are introduced. Then mixture is powdered with calcium stearate, talc and starch, and tablets are pressed with the following application of envelope by the method of increasing. EFFECT: higher efficiency. 3 cl
The study drug, CN-105, will be administered at 1.0 mg/kg every 6 +/- 1 hour. The calculated volumes of study agent will be removed from the vials and transferred to 250 mL of normal saline (0.9% sodium chloride injection, USP). The recorded weight at baseline will be used to determine the appropriate amount of CN-105 drug product to administer. Estimated weight may be used if recorded weight is not available. Each dose of CN-105 or placebo will be administered as a slow IV bolus over 30 minutes.
PANHEMATIN (hemin for injection) is an enzyme inhibitor derived from processed red blood cells. Hemin for injection was known previously as hematin. The term hematin has been used to describe the chemical reaction product of hemin and sodium carbonate solution. Hemin and hematin are iron containing metalloporphyrin complexes with either bound chloride or hydroxide ions, respectively. Chemically hemin is represented as chloro [7,12-diethenyl-3,8,13,17-tetramethyl- 21H,23H-porphine-2,18-dipropanoato(2-)-N21,N22,N23,N24] iron. The structural formula for hemin is:

PANHEMATIN is formatted as a sterile, lyophilized powder for intravenous administration after reconstitution. Each dispensing vial of PANHEMATIN contains the equivalent of 350 mg hemin, 240 mg sodium carbonate and 335 mg of sorbitol. The pH may have been adjusted with hydrochloric acid. When mixed as directed with Sterile Water for Injection, USP, each 48 mL provides the equivalent of approximately 336 mg hematin (7 mg/ mL). The product contains no preservatives.
FIELD: medicinal industry. SUBSTANCE: beet, citrus or apple pectins are extracted with 0.5% solution of ammonium citrate. After filtration electrolyte (0.1 M solution of potassium chloride) is added to the obtained pectin extract and dialyzed through cellophane membrane at 38 C for 24 h. Obtained dialyzate is evaporated under vacuum and treated with 96% ethyl alcohol. Pectins are separated and treated with 5% solution of ammonia at ratio 1: 10 at pH 10.5 for 2 h. Mixture is acidified with hydrochloric acid solution to pH 2 and kept at 18 C followed by the end product isolation. Obtained pectins can be used as detoxifying agents. EFFECT: increased purity and binding activity of the end product. 5 tbl, 2 dwg
Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
The invention relates to a liquid traditional Chinese medicine decoction piece and a preparation method thereof. The liquid traditional Chinese medicine decoction piece is prepared from raw materials of traditional Chinese medicine decoction pieces or crude drugs. The invention is characterized in that the liquid traditional Chinese medicine decoction pieces are spherical or nearspherical particles, and the raw materials are sieved by a screen of 40-200 meshes. The plant drug powder and the animal drug powder in the powder of the raw materials are fine powder in which plant cell organizations and animal plant cell organizations can be seen under the microscope. The liquid traditional Chinese medicine decoction piece does not contain any adhesives or adjuvant materials, and uses water as the forming agent; the particles of the novel decoction piece are manufactured by the modern granulating technology of shaping and shot blasting, and are equal in size, uniform in density and good at liquidity; and the liquid traditional Chinese medicine decoction piece meets the mechanization packing requirements, and realizes the normalization for packing and the quality standardization and the detection modernization of the traditional Chinese medicine decoction piece. The granulating process is a physical change rather than a chemical change, and conforms to the traditional Chinese medicine principle of multi-drug decoction. The invention pushes forward the production modernization and the industrial modernization of the traditional Chinese medicine, and plays an active role in expediting the technology innovation of the traditional Chinese medicine industry.
Wheat lines harboring wild-relative chromosomes can be karyotypically unstable during long-term maintenance. Tissue culture exacerbates chromosomal instability but appears inefficient to induce somatic homoeologous exchange between alien and wheat chromosomes. We assessed if long-term refrigerator storage with regular renewal via self-fertilization, a widely used practice for crop germplasm maintenance, would ensure genetic fidelity of alien addition lines, and explored the possibility of inducing somatic homoeologues exchange by tissue culture. We cytogenetically characterized sampled stock seeds of originally confirmed 12 distinct wheat-Thinopyrum intermedium alien addition lines (dubbed TAI lines), and subjected immature embryos of the TAI lines to tissue culture. We find eight of the 12 TAI lines were karyotypically departed from their original identity as bona fide disomic alien addition lines due to extensive loss of whole-chromosomes of both Th. intermedium and wheat origins during the ca. 3-decade storage. Rampant numerical chromosome variations (NCVs) involving both alien and wheat chromosomes were detected in regenerated plants of all 12 studied TAI lines, but at variable rates among the wheat sub-genomes and chromosomes. Compared with NCVs, structural chromosome variations (SCVs) occurred at substantially lower rates, and no SCV involving the added alien chromosomes was observed. The NCVs manifested only moderate effects on phenotypes of the regenerated plants under field conditions.
The invention relates to a regorafenib tablet pharmaceutical composition and a preparation method thereof and in particular relates to a pharmaceutical composition. The pharmaceutical composition comprises an active pharmaceutical compound, a diluent, a disintegrating agent, an adhesive and a lubricating agent, wherein the active pharmaceutical compound refers to 4-[4-({4-chloro-3-(trifluoromethyl)phenyl]carbamyl}amino)-3-chlorophenoxy]-N-methylpyridine-2-formamide or pharmaceutically acceptable salts, solvates and polymorphism. The pharmaceutical composition has a contact angle of 40-100 degrees, particularly a contact angle of 40-90 degrees, preferably a contact angle of 40-80 degrees, and in particular a contact angle of 40-70 degrees. The pharmaceutical composition disclosed by the invention can be used for treating diseases and disease symptoms mediated by abnormal VEGFR, PDGFR, raf, p38 and/or flt-3 kinase signals. The invention also relates to a method for preparing an anti-tumor pharmaceutical composition. The pharmaceutical composition disclosed by the invention has excellent preparation performance.
PURPOSE:To obtain treated pigment having high water repellency and improved dispersibility, by dispersing completely pigment togehter with a salt soluble in fatty acid into water, dropping slowly an aqueous solution of a soluble salt of Al, Mg, Ti, etc., orientating and adsorbing a formed metal salt on the surface of pigment. CONSTITUTION:Pigment (e.g., titanium oxide, black iron oxide, dolomite pieces) is suspended in water at 3-35wt% concentration, a salt soluble in fatty acid in an amount corresponding to 0.5-10wt% based on the pigment is added to it, it is fully stirred under heating at 40-60 deg.C in the case of necessity so that the pigment is completely dispersed. 1-30wt% aqueous solution of soluble salt such as Al, Mg, Ca, Zn, Zr, Ti, etc. is added slowly to the suspension in such a way that the amont of the soluble salt is 1-3 equivalents based on the salt soluble in fatty acid, to give the pigment wherein the formed metal salt of fatty acid is orientated and adsorbed on the surface of it. Since the metal soup and the pigment do not only coexist, long-time stirring, etc. are not required, the pigment is provided with sufficient water repellency with a small amount of the metal soup.
<P>PROBLEM TO BE SOLVED: To provide a moisture-keeping plant extract having the effects of keeping the moisturizing effects for a long period; and to provide a moisture-keeping external preparation, a cosmetic, a bath agent and a detergent composition.  <P>SOLUTION: The moisture-keeping plant extract comprises an extract of a mixture of Zizyphus jujuba Miller var. inermis Rehder, Cinnamomum cassia Blume, Paeonia lactiflora Pallas, Zingiber officinale Rosco, Grycyrrhiza glabra Linne and Astragalus membranaceus Bunge. The moisture-keeping external preparation, the cosmetic, the bath agent and the detergent composition contain the extract. The product obtained by decocting the crude medicines in prescribed proportions has the same composition as the one called Keishikaougito. The extract of the mixture of the crude medicines contains a moisture-keeping component having the moisture-keeping effects lasting for a long period, and is effective for the prevention, reduction and amelioration of dryness of the skin, rough skin, chaps, cracks, scurf, itching, and inflammatory diseases by external use, and also effective for dryness, looseness, split hair, broken hair, gloss impartment, or the like, of the hair.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2. After 1 week washout, participant will receive 10 minutes of sham tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT. After 1 week washout, participant will receive 10 minutes of cathodal tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT.